We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+47.61%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.49B
AUM Growth
+$63.7M
Cap. Flow
-$72.5M
Cap. Flow %
-4.85%
Top 10 Hldgs %
49.88%
Holding
81
New
8
Increased
11
Reduced
24
Closed
8

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$22.9M
2
AXSM icon
Axsome Therapeutics
AXSM
+$19.4M
3
PRME icon
Prime Medicine
PRME
+$13.3M
4
PCVX icon
Vaxcyte
PCVX
+$12.8M
5
BCAB icon
BioAtla
BCAB
+$12.4M

Top Sells

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$38.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$27.9M
3
ACLX
Arcellx
ACLX
+$22.3M
4
ACET icon
Adicet Bio
ACET
+$12.5M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
51
Ascendis Pharma A/S
ASND
$16.8B
$6.11M 0.41%
50,000
– –
PSTX
52
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$6.09M 0.41%
1,150,000
-700,000
-38% -$3.2M
GHRS icon
53
GH Research
GHRS
$2.08B
$5.76M 0.39%
593,043
– –
ACET icon
54
Adicet Bio
ACET
$74.7M
$5.36M 0.36%
37,500
-50,000
-57% -$12.5M
AMAM
55
DELISTED
Ambrx Biopharma Inc
AMAM
$5.3M 0.35%
2,336,389
– –
ICVX
56
DELISTED
Icosavax, Inc. Common Stock
ICVX
$5.11M 0.34%
643,825
– –
OLMA icon
57
Olema Pharmaceuticals
OLMA
$1.05B
$5.1M 0.34%
2,082,000
– –
KROS icon
58
Keros Therapeutics
KROS
$221M
$4.8M 0.32%
100,000
– –
ELDN icon
59
Eledon Pharmaceuticals
ELDN
$285M
$2.78M 0.19%
1,217,882
-5,618
-0.5% -$13.9K
ELEV
60
DELISTED
Elevation Oncology
ELEV
$1.85M 0.12%
1,952,032
– –
CNTA
61
DELISTED
Centessa Pharmaceuticals
CNTA
$1.74M 0.12%
561,600
-1,411,128
-72% -$5.23M
XFOR icon
62
X4 Pharmaceuticals
XFOR
$460M
$1.62M 0.11%
54,299
+26,611
+96% +$1.26M
DMRA
63
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$1.17M 0.08%
40,810
– –
BHVN icon
64
Biohaven
BHVN
$2.21B
$1.14M 0.08%
+81,963
New +$1.16M
CMMB
65
Chemomab Therapeutics
CMMB
$14.1M
$922K 0.06%
72,042
– –
TRML
66
DELISTED
Tourmaline Bio
TRML
$919K 0.06%
90,065
– –
PYXS icon
67
Pyxis Oncology
PYXS
$236M
$896K 0.06%
668,854
-1
-0% -$2
AUTL
68
Autolus Therapeutics
AUTL
$562M
$745K 0.05%
392,167
– –
YMAB
69
DELISTED
Y-mAbs Therapeutics
YMAB
$732K 0.05%
150,000
– –
LENZ
70
LENZ Therapeutics
LENZ
$168M
$662K 0.04%
28,507
– –
HARP
71
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$392K 0.03%
54,060
– –
BCEL
72
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$255K 0.02%
319,057
– –
ORTX
73
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$95K 0.01%
25,665
– –
GOSS icon
74
Gossamer Bio
GOSS
$87M
– –
-3,198,382
Closed -$38.3M
LLY icon
75
Eli Lilly
LLY
$1.06T
– –
-30,000
Closed -$9.7M
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2022 Portfolio in Review

As of Q4 2022, Cormorant Asset Management held 81 positions worth $1.49B, up 4.5% from $1.43B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Cormorant Asset Management withdrew a net $72.5M in Q4 2022, closing 8 positions and reducing 24 holdings. Its most notable exit was Gossamer Bio, an estimated $38.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in 89bio worth $32.5M.

  • Cormorant Asset Management's largest Q4 2022 buy was 89bio: 2,550,000 shares worth $32.5M.
  • Cormorant Asset Management added most to BioAtla in Q4 2022, an estimated $12.4M increase.
  • Cormorant Asset Management's biggest Q4 2022 reduction was Arcellx, cutting an estimated $22.3M.
  • Cormorant Asset Management fully exited Gossamer Bio in Q4 2022, selling an estimated $38.3M.
  • Cormorant Asset Management's ten largest holdings make up 50% of its $1.49B portfolio in Q4 2022.
  • Cormorant Asset Management opened 8 new positions and closed 8 in Q4 2022.
  • Cormorant Asset Management's portfolio value rose 4.5% quarter-over-quarter to $1.49B.

Based on Cormorant Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.